Genomic Vision Strengthens Its Intellectual Property

Regulatory News:

Genomic Vision (Paris:GV) (FR0011799907 – GV / PEA-PME eligible), a molecular diagnostics company that specializes in the development of diagnostic tests for genetic diseases and cancers using the DNA molecular combing process, today announces that it has been granted three new patents protecting its technology in the United States (US8586723), Japan (JP5461185) and Israel (IL218041). These three new patents cover the genome structural analysis method called the "Genomic Morse Code”, as well as their associated kits, and integrate the first of the 10 patent families that currently make up Genomic Vision proprietary portfolio.

Applied to the molecular combing technique, which enables the direct visualization of large regions of the genome, the Genomic Morse Code makes it possible to get one’s bearings within the genome, locate genetic events and detect potential anomalies. Inspired by traditional Morse Code, where each number and each letter of the alphabet corresponds to a certain pattern, the Genomic Morse Code uses specific markers, also called molecular probes, that can be organized in such a way as to form easily-recognizable unique patterns to locate regions of interest and characterize any mutation.

The Genomic Morse Code strategy was designed by Genomic Vision’s teams to allow the development of highly-efficient diagnostic tests that remain easy to implement within a clinical context. Its generic and modular nature makes it a scalable approach capable of adapting to the complexity of diagnostic applications.

Obtaining these patents guarantees Genomic Vision exclusivity regarding the use of this powerful method and its inclusion in molecular diagnostics tests. The consolidation of this patent family represents consistent and lasting growth in its portfolio of industrial property licenses and rights.

Aaron Bensimon, Genomic Vision’s co-founder and Chairman, says: "These patents further strengthen Genomic Vision’s positioning on the international genetic diagnostics market. Indeed, the Genomic Morse Code is the key that clears the way for diagnostic applications based on molecular combing. In particular, the latest patent granted to Genomic Vision in the United States, the world’s largest genetic test market, is crucial to ensure the protection of its diagnostic products that use this polyvalent genome analysis method.”

???

ABOUT GENOMIC VISION

A spinoff of the Institut Pasteur, Genomic Vision is a molecular diagnostics company specialized in developing diagnostic tests for genetic diseases and cancers. Using "molecular combing”, an innovative technology that allows the direct visualization of individual DNA molecules, Genomic Vision detects quantitative and qualitative variations in the genome that are at the origin of numerous serious pathologies. Having benefited from the financial support of the Institut Pasteur, SGAM AI, Vesalius Biocapital and Quest Diagnostics, the Company is developing a solid portfolio of tests that notably target breast cancer and cancer of the colon. Since 2013, the Company has marketed the CombHeliX FSHD test for identifying a myopathy that is difficult to detect, Facio-scapulo-humeral dystrophy (FSHD), in the United States thanks to a strategic alliance with Quest Diagnostics, the American leader in diagnostic laboratory tests, and in France.

ABOUT MOLECULAR COMBING

DNA molecular combing technology considerably improves the structural and functional analysis of DNA molecules. DNA fibers are stretched out on glass slides, as if "combed”, and uniformly aligned over the whole surface. It is then possible to identify genetic anomalies by locating genes or specific sequences in a patient’s genome using genetic markers, an approach developed by Genomic Vision and patented under the name Genomic Morse Code. This exploration of the entire genome at high resolution via a simple analysis enables the direct visualization of genetic anomalies that are undetectable by other technologies.

For further information, please go to www.genomicvision.com

DISCLAIMER

This press release contains certain forward-looking statements concerning Genomic Vision and its business.

Such forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the prospectus on which the French Financial Market Authority (AMF) granted its visa n° 14-087 on March 19, 2014 and to the development of economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Genomic Vision or not currently considered material by Genomic Vision. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Genomic Vision to be materially different from such forward-looking statements.

This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for GENOMIC VISION shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.